A Study of the Abuse Liability Potential of Cenobamate in Recreational Drug Users

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

53 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-03-08

Study Completion Date

2017-12-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This randomized, single-dose, placebo- and active-controlled, crossover study will evaluate the abuse liability potential of cenobamate in recreational drug users with sedative drug use experience.

In the Qualification phase, subjects will receive a single dose of either alprazolam or placebo in a crossover design, with a wash-out period of at least 24 hours between treatments. Subjects who are clearly able to distinguish the positive control from placebo will be enrolled in the Treatment phase and will be randomized to single oral doses of cenobamate (2 dose levels), alprazolam (2 dose levels), and placebo in a double-blind, double-dummy, 5-way crossover design. Washout-periods between the 5 treatment periods in the Treatment phase will be at least 16 days.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of the Abuse Potential of Lasmiditan in Participants Who Are Recreational Drug Users

NCT03286218

Recreational Drug Use Prescription Drug Abuse (Not Dependent)

COMPLETED PHASE1

Study to Evaluate the Relative Abuse Potential of Almorexant in Recreational Drug Users

NCT01987739

Abuse Potential Study

COMPLETED PHASE1

Study to Evaluate the Abuse Potential of AZD7325 in Healthy Recreational Central Nervous System (CNS) Depressant Users

NCT00902772

Recreational CNS Depressant Use

COMPLETED PHASE1

A Study of Soticlestat in Healthy Adult Nondependent Recreational Drug Users With Central Nervous System (CNS) Depressant Experience

NCT05602818

Healthy Volunteers

COMPLETED PHASE1

A Study of The Abuse Liability Potential of RO4917838 in Recreational Drug Users

NCT01438749

Healthy Volunteer

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Volunteer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Participants Investigators

Double-blind

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Qualification Y

Placebo; administered orally as a single dose of 2 x 100 mg lactose tablets, over-encapsulated (alprazolam placebo)

Group Type PLACEBO_COMPARATOR

Alprazolam Placebo

Intervention Type DRUG

100 mg lactose tablets

Qualification Z

Alprazolam 2.0 mg; administered orally as a single dose of 2 x 1.0 mg alprazolam tablets, over-encapsulated

Group Type ACTIVE_COMPARATOR

Alprazolam

Intervention Type DRUG

0.5 mg and 1.0 mg alprazolam tablets

Treatment A

Placebo; administered orally as a single dose of 4 x cenobamate-matched placebo tablets and 3 x 100 mg lactose tablets, over-encapsulated (alprazolam placebo)

Group Type PLACEBO_COMPARATOR

Alprazolam Placebo

Intervention Type DRUG

100 mg lactose tablets

Cenobamate placebo

Intervention Type DRUG

Sugar pill manufactured to mimic cenobamate 100 mg tablet

Treatment B

Alprazolam 1.5 mg; administered orally as a single dose of 3 x 0.5 mg alprazolam tablets, over-encapsulated and 4 x cenobamate-matched placebo tablets

Group Type ACTIVE_COMPARATOR

Cenobamate placebo

Intervention Type DRUG

Sugar pill manufactured to mimic cenobamate 100 mg tablet

Alprazolam

Intervention Type DRUG

0.5 mg and 1.0 mg alprazolam tablets

Treatment C

Alprazolam 3.0 mg; administered orally as a single dose of 3 x 1.0 mg alprazolam tablets, over-encapsulated and 4 x cenobamate-matched placebo tablets

Group Type ACTIVE_COMPARATOR

Cenobamate placebo

Intervention Type DRUG

Sugar pill manufactured to mimic cenobamate 100 mg tablet

Alprazolam

Intervention Type DRUG

0.5 mg and 1.0 mg alprazolam tablets

Treatment D

Cenobamate, 200 mg; administered orally as a single dose of 2 x 100 mg cenobamate tablets, 2 x cenobamate-matched placebo tablets, and 3 x 100 mg lactose tablets, over-encapsulated (alprazolam placebo)

Group Type EXPERIMENTAL

Alprazolam Placebo

Intervention Type DRUG

100 mg lactose tablets

Cenobamate placebo

Intervention Type DRUG

Sugar pill manufactured to mimic cenobamate 100 mg tablet

Cenobamate

Intervention Type DRUG

100 mg tablet

Treatment E

Cenobamate, 400 mg; administered orally as a single dose of 4 x 100 mg cenobamate tablets and 3 x 100 mg lactose tablets, over-encapsulated (alprazolam placebo)

Group Type EXPERIMENTAL

Alprazolam Placebo

Intervention Type DRUG

100 mg lactose tablets

Cenobamate

Intervention Type DRUG

100 mg tablet

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Alprazolam Placebo

100 mg lactose tablets

Intervention Type DRUG

Cenobamate placebo

Sugar pill manufactured to mimic cenobamate 100 mg tablet

Intervention Type DRUG

Alprazolam

0.5 mg and 1.0 mg alprazolam tablets

Intervention Type DRUG

Cenobamate

100 mg tablet

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Healthy male or female subjects 18 to 55 years of age, inclusive.
2. Body mass index (BMI) within the range of 19.0 to 32.0 kg/m2, inclusive, and a minimum weight of 50.0 kg.
3. Current recreational drug users who have used benzodiazepines for recreational (non-therapeutic) purposes (i.e., for psychoactive effects) at least 5 times in the past year and used benzodiazepines at least once in the 12 weeks before Screening.
4. Female subjects of childbearing potential with male sexual partners must be using and willing to continue using medically acceptable contraception (as specified in Section 4.5.2) for at least 1 month prior to Screening (at least 3 months for oral and transdermal contraceptives) and for at least 30 days after the last study drug administration.
5. Female subjects of non-childbearing potential must meet the criteria specified in Section 4.5.2.
6. Male subjects with female sexual partners of childbearing potential must be using and willing to continue using medically acceptable contraception (as specified in Section 4.5.2) from Screening and for at least 30 days after the last study drug administration.
7. Able to speak, read, and understand English sufficiently to allow completion of all study assessments.
8. Must understand and provide written informed consent, prior to the initiation of any protocol-specific procedures.
9. Must be willing to comply with the requirements and restrictions of the study.

Exclusion Criteria

1. Substance or alcohol dependence within the past 2 years, as defined by the Diagnostic and Statistical Manual of Mental Disorders - Fourth Edition - Text Revision (DSM IV-TR), and/or has ever participated or plans to participate in a substance or alcohol rehabilitation program to treat their substance or alcohol dependence (excluding nicotine and caffeine).
2. Heavy smoker (\>20 cigarettes per day) and/or is unable to abstain from smoking or unable to abstain from the use of prohibited nicotine-containing products for at least 10 hours during the in-clinic periods (including e-cigarettes, pipes, cigars, chewing tobacco, nicotine-topical patches, nicotine gum, or nicotine lozenges).
3. History or presence of clinically significant abnormality as assessed by physical examination, medical history (including cholecystectomy), ECGs, vital signs, or laboratory values, which in the opinion of the investigator would jeopardize the safety of the subject or the validity of the study results.
4. History or presence of myasthenia gravis, severe hepatic insufficiency, severe respiratory insufficiency, sleep apnea syndrome, or acute narrow angle glaucoma.
5. Positive for hepatitis B, hepatitis C, or human immunodeficiency virus (HIV).
6. Evidence of clinically significant hepatic or renal impairment including alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>1.5× the upper limit of normal (ULN), or bilirubin \>1× ULN. Repeat safety laboratory tests are allowed once for Screening, unless the principal investigator and sponsor agree to an additional repeat.
7. Donation or loss of more than 500 mL whole blood within 30 days preceding entry into the Treatment Phase.
8. Difficulty with venous access or unsuitable or unwilling to undergo catheter insertion.
9. Female subjects who are currently pregnant (have a positive pregnancy test) or lactating or who are planning to become pregnant within 30 days of last study drug administration.
10. History of severe allergic reaction (including anaphylaxis) to any substance, or previous status asthmaticus.
11. Subject history of allergy, hypersensitivity, or DRESS syndrome to any drug product including anti-convulsants (e.g., alprazolam, carbamazepine) or related drugs (e.g., other benzodiazepines) or known excipients of any of the drug products in this study. History of a first degree relative with a serious cutaneous drug-induced adverse reaction.
12. Subjects with any history of suicidal ideation or suicidal behavior, as assessed by the Columbia-Suicide Severity Rating Scale (C SSRS; baseline version).
13. Use of a prohibited medication or investigational drug, including exposure to any drugs associated with DRESS syndrome (e.g., allopurinol, minocycline, abacavir, lamotrigine) in the 6 months prior to Screening.
14. Use of a prohibited medication, as specified in Section 4.5.1.
15. Treatment with an investigational drug within 5 times the elimination half-life, if known (e.g., a marketed product), or within 30 days (if the elimination half-life is unknown) prior to the first study drug administration or is concurrently enrolled in any research judged not be scientifically or medically compatible with this study.
16. An employee of the sponsor or research site personnel directly affiliated with this study or their immediate family member defined as a spouse, parent, child or sibling, whether biological or legally adopted.
17. A subject who has pending legal charges or is on probation.
18. A subject who, in the opinion of the investigator or designee, is considered unsuitable or unlikely to comply with the study protocol for any reason.
19. Anyone who has previously been exposed to cenobamate (prior to participation in this study).

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes